Literature DB >> 11549900

Mizoribine ameliorates the tubulointerstitial fibrosis of obstructive nephropathy.

N Sato1, K Shiraiwa, K Kai, A Watanabe, S Ogawa, Y Kobayashi, H Yamagishi-Imai, Y Utsunomiya, T Mitarai.   

Abstract

Mizoribine has been shown to possess an immunosuppressive action that inhibits the proliferation of lymphocytes selectively by interfering with inosine monophosphate dehydrogenase. Recent studies have demonstrated that mizoribine improves renal tubulointerstitial fibrosis in the rat model of unilateral ureteral obstruction (UUO) by inhibiting the infiltration of macrophages. We, therefore, examined the dose dependency of the suppressive effect of mizoribine on the infiltration of interstitial macrophages and T lymphocytes and the interstitial volume in UUO-treated kidneys. Furthermore, we investigated the expression of osteopontin (OPN), known to be a chemoattractant protein for macrophages, in the renal cortex. In rats with UUO, the interstitial volume was markedly expanded, and macrophage and T lymphocyte infiltration in the interstitium and the expression of OPN in the cortical tubules were greatly increased. Treatment with mizoribine ameliorated the increase in interstitial volume induced by UUO. Interstitial infiltration of macrophages and T lymphocytes was dose dependently suppressed by mizoribine, and the decreased macrophage infiltration was correlated with inhibition of tubular OPN expression. These results suggest that mizoribine has a beneficial effect on several steps contributing to the progression of tubulointerstitial fibrosis caused by obstruction of the ureter. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549900     DOI: 10.1159/000046065

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  8 in total

1.  Mizoribine reduces serum KL-6 levels in ANCA-associated vasculitis.

Authors:  Shogo Fujita; Kouichi Hirayama; Yujiro Ogawa; Homare Shimohata; Masaki Kobayashi
Journal:  Clin Exp Nephrol       Date:  2009-12-05       Impact factor: 2.801

Review 2.  Mizoribine in the treatment of pediatric-onset glomerular disease.

Authors:  Hiroshi Tanaka; Kazushi Tsuruga; Taddatsu Imaizumi
Journal:  World J Pediatr       Date:  2015-03-09       Impact factor: 2.764

3.  Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis.

Authors:  Hiroshi Tanaka; Eishin Oki; Kazushi Tsuruga; Tomomi Aizawa-Yashiro; Yuya Ito; Norihiro Sato; Yukihiko Kawasaki; Junzo Suzuki
Journal:  Clin Rheumatol       Date:  2010-05-19       Impact factor: 2.980

4.  Role of inflammation in túbulo-interstitial damage associated to obstructive nephropathy.

Authors:  María T Grande; Fernando Pérez-Barriocanal; José M López-Novoa
Journal:  J Inflamm (Lond)       Date:  2010-04-22       Impact factor: 4.981

5.  Use of mizoribine as a rescue drug for steroid-resistant pediatric IgA nephropathy.

Authors:  Yohei Ikezumi; Toshiaki Suzuki; Tamaki Karasawa; Hiroshi Kawachi; David J Nikolic-Paterson; Makoto Uchiyama
Journal:  Pediatr Nephrol       Date:  2007-11-24       Impact factor: 3.714

6.  Methylprednisolone pulse therapy combined with mizoribine following tonsillectomy for immunoglobulin A nephropathy: clinical remission rate, steroid sparing effect, and maintenance of renal function.

Authors:  Tomohiro Kaneko; Akio Hirama; Kae Ueda; Teppei Fujino; Koichi Utsumi; Yasuhiko Iino; Yasuo Katayama
Journal:  Clin Exp Nephrol       Date:  2010-10-23       Impact factor: 2.801

7.  Successful treatment of adult IgA nephropathy with nephrotic-level proteinuria by combination therapy including long-term coadministration of mizoribine.

Authors:  Hideo Okonogi; Tetsuya Kawamura; Nanae Matsuo; Yasuto Takahashi; Izumi Yamamoto; Hiraku Yoshida; Kentaro Koike; Takashi Yokoo; Kensuke Joh; Yasunori Utsunomiya; Kazushige Hanaoka; Tatsuo Hosoya
Journal:  Case Rep Nephrol Urol       Date:  2012-06-05

8.  Influence of cyclosporine A on glomerular growth and the effect of mizoribine and losartan on cyclosporine nephrotoxicity in young rats.

Authors:  Ji Hong Kim; Yeon Hee Lee; Beom Jin Lim; Hyeon Joo Jeong; Pyung Kil Kim; Jae Il Shin
Journal:  Sci Rep       Date:  2016-03-07       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.